Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $1.7 billion.

  • Legend Biotech's Liabilities and Shareholders Equity fell 131.79% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 billion, marking a year-over-year decrease of 655.32%. This contributed to the annual value of $1.7 billion for FY2024, which is 965.35% down from last year.
  • Per Legend Biotech's latest filing, its Liabilities and Shareholders Equity stood at $1.7 billion for Q3 2025, which was down 131.79% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Liabilities and Shareholders Equity peaked at $875.1 billion during Q2 2021, and registered a low of $813.8 million during Q3 2021.
  • Over the past 5 years, Legend Biotech's median Liabilities and Shareholders Equity value was $1.7 billion (recorded in 2025), while the average stood at $89.0 billion.
  • Over the last 5 years, Legend Biotech's Liabilities and Shareholders Equity had its largest YoY gain of 5503.06% in 2021, and its largest YoY loss of 9988.52% in 2021.
  • Quarter analysis of 5 years shows Legend Biotech's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then rose by 18.89% to $1.3 billion in 2022, then soared by 38.89% to $1.8 billion in 2023, then fell by 9.65% to $1.7 billion in 2024, then increased by 2.56% to $1.7 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.7 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.6 billion for Q1 2025.